Dupilumab offers a new option for the management of moderate-to-severe atopic dermatitis not responsive to traditional therapy. It has been shown to reduce atopic dermatitis symptoms by 75% in most patients for periods up to one year and is generally well tolerated. While dupilumab offers significant advantages over other therapies and may minimize reliance on long-term corticosteroid administration, its cost will likely limit its use.
Pediatr Pharm. 2019;25(6) © 2019 University of Virginia